IκB Kinase α is required for development and progression of KRAS-mutant lung adenocarcinoma

Although oncogenic activation of NFkB has been identified in various tumors, the NFkB–activating kinases (inhibitor of NFkB kinases, IKK) responsible for this are elusive. In this study, we determined the role of IKKa and IKKb in KRAS-mutant lung adenocarcinomas induced by the carcinogen urethane an...

Full description

Bibliographic Details
Main Authors: Vreka, M, Lilis, I, Papageorgopoulou, M, Giotopoulou, G, Lianou, M, Giopanou, I, Kanellakis, N, Spella, M, Agalioti, T, Armenis, V, Goldmann, T, Marwitz, S, Yull, F, Blackwell, T, Pasparakis, M, Marazioti, A, Stathopoulos, G
Format: Journal article
Language:English
Published: American Association for Cancer Research 2018
_version_ 1797087004445376512
author Vreka, M
Lilis, I
Papageorgopoulou, M
Giotopoulou, G
Lianou, M
Giopanou, I
Kanellakis, N
Spella, M
Agalioti, T
Armenis, V
Goldmann, T
Marwitz, S
Yull, F
Blackwell, T
Pasparakis, M
Marazioti, A
Stathopoulos, G
author_facet Vreka, M
Lilis, I
Papageorgopoulou, M
Giotopoulou, G
Lianou, M
Giopanou, I
Kanellakis, N
Spella, M
Agalioti, T
Armenis, V
Goldmann, T
Marwitz, S
Yull, F
Blackwell, T
Pasparakis, M
Marazioti, A
Stathopoulos, G
author_sort Vreka, M
collection OXFORD
description Although oncogenic activation of NFkB has been identified in various tumors, the NFkB–activating kinases (inhibitor of NFkB kinases, IKK) responsible for this are elusive. In this study, we determined the role of IKKa and IKKb in KRAS-mutant lung adenocarcinomas induced by the carcinogen urethane and by respiratory epithelial expression of oncogenic KRASG12D. Using NFkB reporter mice and conditional deletions of IKKa and IKKb, we identified two distinct early and late activation phases of NFkB during chemical and genetic lung adenocarcinoma development, which were characterized by nuclear translocation of RelB, IkBb, and IKKa in tumor-initiated cells. IKKa was a cardinal tumor promoter in chemical and genetic KRAS-mutant lung adenocarcinoma, and respiratory epithelial IKKa-deficient mice were markedly protected from the disease. IKKa specifically cooperated with mutant KRAS for tumor induction in a cell-autonomous fashion, providing mutant cells with a survival advantage in vitro and in vivo. IKKa was highly expressed in human lung adenocarcinoma, and a heat shock protein 90 inhibitor that blocks IKK function delivered superior effects against KRAS-mutant lung adenocarcinoma compared with a specific IKKb inhibitor. These results demonstrate an actionable requirement for IKKa in KRAS-mutant lung adenocarcinoma, marking the kinase as a therapeutic target against this disease. Significance: These findings report a novel requirement for IKKa in mutant KRAS lung tumor formation, with potential therapeutic applications.
first_indexed 2024-03-07T02:29:57Z
format Journal article
id oxford-uuid:a6e58f0e-9440-410f-bd37-4d88a94c13a5
institution University of Oxford
language English
last_indexed 2024-03-07T02:29:57Z
publishDate 2018
publisher American Association for Cancer Research
record_format dspace
spelling oxford-uuid:a6e58f0e-9440-410f-bd37-4d88a94c13a52022-03-27T02:50:50ZIκB Kinase α is required for development and progression of KRAS-mutant lung adenocarcinomaJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:a6e58f0e-9440-410f-bd37-4d88a94c13a5EnglishSymplectic Elements at OxfordAmerican Association for Cancer Research2018Vreka, MLilis, IPapageorgopoulou, MGiotopoulou, GLianou, MGiopanou, IKanellakis, NSpella, MAgalioti, TArmenis, VGoldmann, TMarwitz, SYull, FBlackwell, TPasparakis, MMarazioti, AStathopoulos, GAlthough oncogenic activation of NFkB has been identified in various tumors, the NFkB–activating kinases (inhibitor of NFkB kinases, IKK) responsible for this are elusive. In this study, we determined the role of IKKa and IKKb in KRAS-mutant lung adenocarcinomas induced by the carcinogen urethane and by respiratory epithelial expression of oncogenic KRASG12D. Using NFkB reporter mice and conditional deletions of IKKa and IKKb, we identified two distinct early and late activation phases of NFkB during chemical and genetic lung adenocarcinoma development, which were characterized by nuclear translocation of RelB, IkBb, and IKKa in tumor-initiated cells. IKKa was a cardinal tumor promoter in chemical and genetic KRAS-mutant lung adenocarcinoma, and respiratory epithelial IKKa-deficient mice were markedly protected from the disease. IKKa specifically cooperated with mutant KRAS for tumor induction in a cell-autonomous fashion, providing mutant cells with a survival advantage in vitro and in vivo. IKKa was highly expressed in human lung adenocarcinoma, and a heat shock protein 90 inhibitor that blocks IKK function delivered superior effects against KRAS-mutant lung adenocarcinoma compared with a specific IKKb inhibitor. These results demonstrate an actionable requirement for IKKa in KRAS-mutant lung adenocarcinoma, marking the kinase as a therapeutic target against this disease. Significance: These findings report a novel requirement for IKKa in mutant KRAS lung tumor formation, with potential therapeutic applications.
spellingShingle Vreka, M
Lilis, I
Papageorgopoulou, M
Giotopoulou, G
Lianou, M
Giopanou, I
Kanellakis, N
Spella, M
Agalioti, T
Armenis, V
Goldmann, T
Marwitz, S
Yull, F
Blackwell, T
Pasparakis, M
Marazioti, A
Stathopoulos, G
IκB Kinase α is required for development and progression of KRAS-mutant lung adenocarcinoma
title IκB Kinase α is required for development and progression of KRAS-mutant lung adenocarcinoma
title_full IκB Kinase α is required for development and progression of KRAS-mutant lung adenocarcinoma
title_fullStr IκB Kinase α is required for development and progression of KRAS-mutant lung adenocarcinoma
title_full_unstemmed IκB Kinase α is required for development and progression of KRAS-mutant lung adenocarcinoma
title_short IκB Kinase α is required for development and progression of KRAS-mutant lung adenocarcinoma
title_sort iκb kinase α is required for development and progression of kras mutant lung adenocarcinoma
work_keys_str_mv AT vrekam ikbkinaseaisrequiredfordevelopmentandprogressionofkrasmutantlungadenocarcinoma
AT lilisi ikbkinaseaisrequiredfordevelopmentandprogressionofkrasmutantlungadenocarcinoma
AT papageorgopouloum ikbkinaseaisrequiredfordevelopmentandprogressionofkrasmutantlungadenocarcinoma
AT giotopouloug ikbkinaseaisrequiredfordevelopmentandprogressionofkrasmutantlungadenocarcinoma
AT lianoum ikbkinaseaisrequiredfordevelopmentandprogressionofkrasmutantlungadenocarcinoma
AT giopanoui ikbkinaseaisrequiredfordevelopmentandprogressionofkrasmutantlungadenocarcinoma
AT kanellakisn ikbkinaseaisrequiredfordevelopmentandprogressionofkrasmutantlungadenocarcinoma
AT spellam ikbkinaseaisrequiredfordevelopmentandprogressionofkrasmutantlungadenocarcinoma
AT agaliotit ikbkinaseaisrequiredfordevelopmentandprogressionofkrasmutantlungadenocarcinoma
AT armenisv ikbkinaseaisrequiredfordevelopmentandprogressionofkrasmutantlungadenocarcinoma
AT goldmannt ikbkinaseaisrequiredfordevelopmentandprogressionofkrasmutantlungadenocarcinoma
AT marwitzs ikbkinaseaisrequiredfordevelopmentandprogressionofkrasmutantlungadenocarcinoma
AT yullf ikbkinaseaisrequiredfordevelopmentandprogressionofkrasmutantlungadenocarcinoma
AT blackwellt ikbkinaseaisrequiredfordevelopmentandprogressionofkrasmutantlungadenocarcinoma
AT pasparakism ikbkinaseaisrequiredfordevelopmentandprogressionofkrasmutantlungadenocarcinoma
AT maraziotia ikbkinaseaisrequiredfordevelopmentandprogressionofkrasmutantlungadenocarcinoma
AT stathopoulosg ikbkinaseaisrequiredfordevelopmentandprogressionofkrasmutantlungadenocarcinoma